Like any street drug, crystal meth can be cut with anything- from baking power, chalk, or talc, to other drugs. Thanks!
Monoamine oxidase inhibitors
A dopamine agonist is a compound that activates dopamine receptors in the absence of dopamine. Dopamine agonists activate signaling pathways through the dopamine receptor and trimeric G-proteins, ultimately leading to changes in gene transcription.
Some medical drugs act as dopamine agonists and can treat hypodopaminergic (low dopamine) conditions; they are typically used for treating Parkinson's disease, attention deficit/hyperactivity disorder (in the form of stimulants) and certain pituitary tumors (prolactinoma), and may be useful for restless legs syndrome (RLS). Both Requip (Ropinirole) and Mirapex (Pramipexole) are FDA-approved for the treatment of RLS. There is also an ongoing clinical trial to test the effectiveness of the dopamine agonist Requip (ropinirole) in reversing the symptoms of SSRI-induced sexual dysfunction and Post-SSRI sexual dysfunction (PSSD). Additionally, a systematic review and meta-analysis concluded that prophylactic treatment with cabergoline reduces the incidence, but not the severity, of ovarian hyperstimulation syndrome (OHSS), without compromising pregnancy outcomes, in females undergoing stimulated cycles of in vitro fertilization (IVF).
Montana Meth Project
Monoamine oxidase inhibitors (MAOIs) are chemicals which inhibit the activity of the monoamine oxidase enzyme family. They have a long history of use as medications prescribed for the treatment of depression. They are particularly effective in treating atypical depression.]citation needed[ They are also used in the treatment of Parkinson's Disease and several other disorders.
Because of potentially lethal dietary and drug interactions, monoamine oxidase inhibitors have historically been reserved as a last line of treatment, used only when other classes of antidepressant drugs (for example selective serotonin reuptake inhibitors and tricyclic antidepressants) have failed. New research into MAOIs indicate that much of the concern over their dangerous dietary side effects stems from misconceptions and misinformation, and that despite proven effectiveness of this class of drugs, it is underutilized and misunderstood in the medical profession. New research also questions the validity of the perceived severity of dietary reactions, which has historically been based on outdated research.
Party and play
The Montana Meth Project (MMP) is a Montana-based non-profit organization founded by businessman Thomas Siebel which seeks to reduce methamphetamine use, particularly among teenagers. The main venture of the MMP is a saturation-level advertising campaign of television, radio, print, and internet ads that graphically depict the negative consequences of methamphetamine use. Common elements are the deterioration of each teenage subject's health and living conditions, amphetamine psychosis, moral compromise, and regret. As of 2010, the Meth Project has expanded its media campaign into seven additional states. As of March 13, 2013 the Meth Project, the umbrella organization of the Montana Meth Project, joined the Partnership at Drugfree.org in their efforts to reduce substance abuse among teens.
Health Medical Pharma
Health Medical Pharma
Party and play (PNP and PnP) is a phenomenon and subculture of recreational drug users who engage in sexual activities with one another, either one-on-one or in groups. It is also called chemical session, chem session, and partying.
The term is often but not always used by and associated with gay people and men who have sex with men (MSM). The drug of choice is typically methamphetamine, known as crystal or tina in the gay community. Other "party drugs" such as MDMA and GHB are less associated with this term. It has been called an "epidemic" in the gay community.